金石亚药(300434) - 2025 Q4 - 年度业绩预告

Financial Projections - The company expects a net profit of approximately 118.91 million yuan for the year 2025, representing a year-on-year growth of 29.58%[4] - The net profit after deducting non-recurring gains and losses is projected to be around 97.90 million yuan, reflecting an 18.96% increase compared to the previous year[4] Profit Drivers - The increase in profit is attributed to the successful commercialization of R&D results in the new materials and machinery sectors, as well as a rise in sales of anti-influenza virus products due to market demand[6] - Non-recurring gains and losses are expected to impact net profit by approximately 21.01 million yuan[6] Operational Efficiency - The company has implemented effective budget optimization and cost control measures to support improved operating performance[6] Financial Reporting - The financial data presented is preliminary and will be detailed in the 2025 annual report, pending audit by the accounting firm[7]